首页> The New England journal of medicine> An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

导出 OA

翻译打印收藏纠错

第一作者： Lisa A,Jackson

第一单位： From Kaiser Permanente Washington Health Research Institute (L.A.J.) and the Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute (R.N.C.) - both in Seattle; the Department of Medicine, Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta (E.J.A., E.P.), and Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur (N.G.R., M.P.M.) - both in Georgia; the Division of Microbiology and Infectious Diseases (P.C.R., M. Makhene, W.B., R.P.-T., J.H.B.) and the Vaccine Research Center (A.M., B.F., N.A.D.-R., K.S.C., K.M.M., S.O., S.D.S., P.A.S., M.P., J.R.M., J.E.L., B.S.G.), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, the University of Maryland School of Medicine, Baltimore (K.M.N.), and the Emmes Company, Rockville (M. Makowski, J.A., K.C.) - all in Maryland; the Departments of Pediatrics (J.D.C., M.R.D., L.J.S., A.J.P.) and Pathology, Microbiology, and Immunology (M.R.D.), and the Vanderbilt Institute for Infection, Immunology, and Inflammation (J.D.C., M.R.D., A.J.P.), Vanderbilt University Medical Center, Nashville; and Moderna, Cambridge, MA (H.B., W.S.).

作者： Lisa A,Jackson ^[1] ; Evan J,Anderson ^[1] ; Nadine G,Rouphael ^[1] ; Paul C,Roberts ^[1] ; Mamodikoe,Makhene ^[1] ; Rhea N,Coler ^[1] ; Michele P,McCullough ^[1] ; James D,Chappell ^[1] ; Mark R,Denison ^[1] ; Laura J,Stevens ^[1] ; Andrea J,Pruijssers ^[1] ; Adrian,McDermott ^[1] ; Britta,Flach ^[1] ; Nicole A,Doria-Rose ^[1] ; Kizzmekia S,Corbett ^[1] ; Kaitlyn M,Morabito ^[1] ; Sijy,O'Dell ^[1] ; Stephen D,Schmidt ^[1] ; Phillip A,Swanson ^[1] ; Marcelino,Padilla ^[1] ; John R,Mascola ^[1] ; Kathleen M,Neuzil ^[1] ; Hamilton,Bennett ^[1] ; Wellington,Sun ^[1] ; Etza,Peters ^[1] ; Mat,Makowski ^[1] ; Jim,Albert ^[1] ; Kaitlyn,Cross ^[1] ; Wendy,Buchanan ^[1] ; Rhonda,Pikaart-Tautges ^[1] ; Julie E,Ledgerwood ^[1] ; Barney S,Graham ^[1] ; John H,Beigel ^[1] ; mRNA-1273 Study Group

作者单位： From Kaiser Permanente Washington Health Research Institute (L.A.J.) and the Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute (R.N.C.) - both in Seattle; the Department of Medicine, Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta (E.J.A., E.P.), and Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur (N.G.R., M.P.M.) - both in Georgia; the Division of Microbiology and Infectious Diseases (P.C.R., M. Makhene, W.B., R.P.-T., J.H.B.) and the Vaccine Research Center (A.M., B.F., N.A.D.-R., K.S.C., K.M.M., S.O., S.D.S., P.A.S., M.P., J.R.M., J.E.L., B.S.G.), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, the University of Maryland School of Medicine, Baltimore (K.M.N.), and the Emmes Company, Rockville (M. Makowski, J.A., K.C.) - all in Maryland; the Departments of Pediatrics (J.D.C., M.R.D., L.J.S., A.J.P.) and Pathology, Microbiology, and Immunology (M.R.D.), and the Vanderbilt Institute for Infection, Immunology, and Inflammation (J.D.C., M.R.D., A.J.P.), Vanderbilt University Medical Center, Nashville; and Moderna, Cambridge, MA (H.B., W.S.). ^[1]